Pharma News

Sandoz announces the release of positive results from the integrated ROSALIA Phase 3 clinical trial study for its proposed biosimilar denosumab.

Chronic diseases often lead to fibrosis, a condition in which organ tissue suffers from excessive scarring. Researchers at the University of Zurich have now developed an immunotherapy that specifically targets the cause – activated fibroblasts – while leaving normal connective tissue cells unharmed. If this approach is also found to work in humans, it could lead to an effective treatment for fibrosis.

Adults with ADHD are at greater risk of developing a range of cardiovascular diseases than those without the condition, according to a large observational study led by researchers at Karolinska Institutet and Örebro University. The researchers say the findings, published in the journal World Psychiatry, underscore the need to monitor cardiovascular health in people with ADHD.

Mallinckrodt plc a global specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved Terlivaz (terlipressin) for injection. Terlivaz is the first and only FDA-approved product indicated to improve kidney function in adults with hepatorenal syndrome (HRS) with rapid reduction in kidney function, an acute and life-threatening condition requiring hospitalization.

Pfizer Inc announced that the first participants have been dosed in a pivotal Phase 3 clinical trial to evaluate the efficacy, safety, tolerability and immunogenicity of the company’s quadrivalent modified RNA (modRNA) influenza vaccine candidate in approximately 25,000 healthy U.S. adults.

The Federal Executive Council of Nigeria has approved the process to set up a vaccine production plant in Ota, Ogun State with help of Serum Institute of India which will join hands with Bio Vaccine Nigeria, to build their manufacturing plant in Nigeria.

The Minister of Health, Dr Osagie Ehanire said yesterday, "The council considered a memorandum from the Ministry of Health today, which has to do with the first stage in indigenizing vaccine production in Nigeria, the standard programme on immunization, not COVID-19 vaccine."

Novartis announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will bolster its capacity and capabilities for early technical development of biologics. Spanning both drug substance and drug product development, the multi-year investment will be implemented across existing Novartis locations in Switzerland, Slovenia and Austria, strengthening Novartis ability to deliver on the increasing growth and diversity of its early-stage biotherapeutics portfolio.

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now, UC San Francisco researchers have developed a drug that overcomes some of these barriers, marking cancer cells for destruction by the immune system.

A pathogenic fungus undergoes a remarkable transformation once it enters the body, allowing it to infect the brain, according to new research by scientists at University of Utah Health. Studies in mice show that as the fungal intruder travels to different organs, it changes in size and acquires characteristics that help infection to spread, all in a matter of days.